Navigation Links
CryoLife Announces Release Date and Teleconference Call Details for 2012 Fourth Quarter and Year End Financial Results
Date:1/31/2013

ATLANTA, Jan. 31, 2013 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a leading tissue processing and medical device company focused on cardiac and vascular surgery, announced today that 2012 fourth quarter and year end financial results will be released on Thursday, February 14, 2013.  On that day, the Company will hold a teleconference call and live webcast at 10:00 a.m. Eastern Time to discuss the results, followed by a question and answer session hosted by Steven G. Anderson , president and chief executive officer of CryoLife, Inc.

To listen to the live teleconference, please dial 201-689-8261 a few minutes prior to 10:00 a.m.  A replay of the teleconference will be available February 14 through February 21 and can be accessed by calling (toll free) 877-660-6853 or 201-612-7415.  The conference number for the replay is 408394.

The live webcast and replay can be accessed by going to the Investor Relations section of the CryoLife website at www.cryolife.com and selecting the heading Webcasts & Presentations. In addition, a copy of the earnings press release, which will contain financial and statistical information for the completed quarter and fiscal year, can be accessed on the Investor Relations section of the CryoLife website.

About CryoLife, Inc.
Founded in 1984, CryoLife, Inc. is a leader in the processing and distribution of implantable living human tissues for use in cardiac and vascular surgeries throughout the U.S., certain countries in Europa, and Canada.  CryoLife's CryoValve® SG pulmonary heart valve, processed using CryoLife's proprietary SynerGraft® technology, has FDA 510(k) clearance for the replacement of diseased, damaged, malformed, or malfunctioning native or prosthetic pulmonary valves.
'/>"/>

SOURCE CryoLife, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. CryoLife Receives Expanded Indication for BioFoam in Europe
2. CryoLife to Participate in Lazard Capital Markets 9th Annual Healthcare Conference
3. CryoLife Reports 13% Revenue Growth for Third Quarter 2012
4. CryoLife Announces Initiation of Quarterly Cash Dividend
5. CryoLife Reports 13% Revenue Growth for Second Quarter 2012
6. CryoLife Announces Release Date and Teleconference Call Details for 2012 Second Quarter Financial Results
7. CryoLife to Participate in 3rd Annual Benchmark Company, LLC One-on-One Investor Conference
8. CryoLife Completes Acquisition of Hemosphere
9. CryoLife Reports Record Quarterly Revenues in First Quarter of 2012
10. Blue Belt Technologies Announces First U.S. Sale of NavioPFS Surgical System
11. IDEV Announces Results from Revascularization with Supera on Real World Patients (RESTORE) Study, Demonstrating Positive Clinical Outcomes in Significantly Diseased Patients with Long Lesions
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... YORK , July 29, 2014 /PRNewswire-iReach/ -- ... the basis of products, methods, applications, end users, ... highest growth in the microbial identification market. This ... consumable costs (per test) and the time required ... and continuous technological advancements. Furthermore, genotypic methods have ...
(Date:7/29/2014)... THOUSAND OAKS, Calif., July 29, 2014 Amgen ... for the second quarter of 2014. Key results include: ... million, with 8 percent product sales growth driven by ... (etanercept), Kyprolis ® (carfilzomib), Prolia ® (denosumab) ... grew 25 percent to $2.37, driven by higher revenues ...
(Date:7/29/2014)... LOUIS, July 29, 2014  Express Scripts Holding Company ... net income attributable to Express Scripts stockholders of $515.2 ... diluted share, as detailed in Table 4, was $1.23 ... are well positioned to serve our clients with scale, alignment ... to improve the health outcomes of our members," stated George ...
Breaking Medicine Technology:Microbial Identification Market Growing at 5.9% CAGR to 2019: Global Forecast in New Research Report Available at ReportsnReports.com 2Microbial Identification Market Growing at 5.9% CAGR to 2019: Global Forecast in New Research Report Available at ReportsnReports.com 3Microbial Identification Market Growing at 5.9% CAGR to 2019: Global Forecast in New Research Report Available at ReportsnReports.com 4Microbial Identification Market Growing at 5.9% CAGR to 2019: Global Forecast in New Research Report Available at ReportsnReports.com 5Microbial Identification Market Growing at 5.9% CAGR to 2019: Global Forecast in New Research Report Available at ReportsnReports.com 6Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 2Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 3Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 4Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 5Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 6Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 7Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 8Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 9Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 10Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 11Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 12Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 13Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 14Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 15Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 16Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 17Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 18Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 19Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 20Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 21Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 22Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 23Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 24Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 25Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 2Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 3Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 4Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 5Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 6Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 7
... but,Underscore Need for Improved Patient Communication, Lifestyle,Management ... Elevated,Blood Pressure, NEW YORK, May 19, 2007 ... Harris Interactive(R) for the Hypertension Education,Foundation (HEF) ... Inc. (ASH) Twenty-Second Annual Scientific Meeting,and Exposition ...
... SAN FRANCISCO--(BUSINESS WIRE)--May 21, 2007 - Medical,professionals ... problem of,hospital-acquired gram-negative pneumonia may have a ... candidate being,developed by Nektar Therapeutics (Nasdaq:NKTR)., Results ... the use of,NKTR-061 (Inhaled Amikacin) to treat ...
Cached Medicine Technology:Hypertension Education Foundation Survey Results Announced At,American Society For Hypertension Annual Meeting Suggests Improved,Control Of High Blood Pressure, But Misconceptions Still Exist 2Hypertension Education Foundation Survey Results Announced At,American Society For Hypertension Annual Meeting Suggests Improved,Control Of High Blood Pressure, But Misconceptions Still Exist 3Hypertension Education Foundation Survey Results Announced At,American Society For Hypertension Annual Meeting Suggests Improved,Control Of High Blood Pressure, But Misconceptions Still Exist 4Hypertension Education Foundation Survey Results Announced At,American Society For Hypertension Annual Meeting Suggests Improved,Control Of High Blood Pressure, But Misconceptions Still Exist 5Hypertension Education Foundation Survey Results Announced At,American Society For Hypertension Annual Meeting Suggests Improved,Control Of High Blood Pressure, But Misconceptions Still Exist 6Hypertension Education Foundation Survey Results Announced At,American Society For Hypertension Annual Meeting Suggests Improved,Control Of High Blood Pressure, But Misconceptions Still Exist 7Nektar Threraputics Announces Phase 2a Clinical Results Regarding,the use of NKTR-061 (Inhaled Amikacin) to Treat Gram-Negative,Hospital-Acquired Pneumonia Presented at the Annual American,Thoracic Society International Conference 2Nektar Threraputics Announces Phase 2a Clinical Results Regarding,the use of NKTR-061 (Inhaled Amikacin) to Treat Gram-Negative,Hospital-Acquired Pneumonia Presented at the Annual American,Thoracic Society International Conference 3Nektar Threraputics Announces Phase 2a Clinical Results Regarding,the use of NKTR-061 (Inhaled Amikacin) to Treat Gram-Negative,Hospital-Acquired Pneumonia Presented at the Annual American,Thoracic Society International Conference 4Nektar Threraputics Announces Phase 2a Clinical Results Regarding,the use of NKTR-061 (Inhaled Amikacin) to Treat Gram-Negative,Hospital-Acquired Pneumonia Presented at the Annual American,Thoracic Society International Conference 5Nektar Threraputics Announces Phase 2a Clinical Results Regarding,the use of NKTR-061 (Inhaled Amikacin) to Treat Gram-Negative,Hospital-Acquired Pneumonia Presented at the Annual American,Thoracic Society International Conference 6Nektar Threraputics Announces Phase 2a Clinical Results Regarding,the use of NKTR-061 (Inhaled Amikacin) to Treat Gram-Negative,Hospital-Acquired Pneumonia Presented at the Annual American,Thoracic Society International Conference 7Nektar Threraputics Announces Phase 2a Clinical Results Regarding,the use of NKTR-061 (Inhaled Amikacin) to Treat Gram-Negative,Hospital-Acquired Pneumonia Presented at the Annual American,Thoracic Society International Conference 8Nektar Threraputics Announces Phase 2a Clinical Results Regarding,the use of NKTR-061 (Inhaled Amikacin) to Treat Gram-Negative,Hospital-Acquired Pneumonia Presented at the Annual American,Thoracic Society International Conference 9Nektar Threraputics Announces Phase 2a Clinical Results Regarding,the use of NKTR-061 (Inhaled Amikacin) to Treat Gram-Negative,Hospital-Acquired Pneumonia Presented at the Annual American,Thoracic Society International Conference 10Nektar Threraputics Announces Phase 2a Clinical Results Regarding,the use of NKTR-061 (Inhaled Amikacin) to Treat Gram-Negative,Hospital-Acquired Pneumonia Presented at the Annual American,Thoracic Society International Conference 11
(Date:7/29/2014)... The One Minute Herpes Cure review indicates that ... medicine specialist. Alison Freeman wanted to show her patients some ... interested in finding out more about this method can easily ... it is currently available in online format. , In the ... herbal medicine tips that can help them achieve a cure ...
(Date:7/29/2014)... Daily Gossip reveals in its Nasal Polyps Treatment Miracle review ... his condition with the use of this method too. In ... , He claimed that he was able to cure ... Since his method turned out being so effective, he decided ... , The Nasal Polyps Treatment Miracle program was created ...
(Date:7/29/2014)... 2014 Diabetes is a common condition diagnosed ... sugar levels are increased, while the production of insulin is ... pancreas and which is needed by the body to regulate ... can be very dangerous, as there are numerous complications that ... about this disorder and read a complex review of Matt ...
(Date:7/29/2014)... 29, 2014 The Natural Multiple Sclerosis ... inside story to Gary M. Levin’s cure program. ... method for this serious disorder. Levin says that multiple ... that can be found in patients. , Dr. ... For many years, Levin has worked with patients suffering ...
(Date:7/29/2014)... Daily Gossip indicates in its Natural Cure for Yeast ... sufferer who is looking for an all-natural holistic cure for ... program, Sarah Summer, says that her method is 100 percent ... Actually, this is the reason why she was so determined ... Natural Cure for Yeast Infection review indicates that ...
Breaking Medicine News(10 mins):Health News:One Minute to Herpes Cure Review Reveals Simplest Herpes Treatment 2Health News:Nasal Polyps Treatment Miracle Review Reveals How to Cure Nasal Polyps Without Surgery 2Health News:Reverse Your Diabetes Today Review Exposes Matt Traverso’s New eBook 2Health News:Natural Multiple Sclerosis Treatment Review Reveals the Inside Story to Gary M. Levin’s Cure Program 2Health News:Natural Cure for Yeast Infection Review Reveals Sarah Summer’s Healing Method 2
... 25 The University of Texas ... add Elekta,s Leksell Gamma Knife (R) Perfexion(TM), ... to treat one or more lesions in the ... oncology department.(Photo: http://www.newscom.com/cgi-bin/prnh/20090225/CL74742 )"Leksell Gamma Knife ...
... CAMBRIDGE, Mass. and GAITHERSBURG, Md., Feb. 25 ... Inc., a systems biology company focused on ... better develop novel therapeutics, molecular diagnostics and ... signed a partnership agreement with Gene Logic, ...
... Feb. 25 Aton Pharma, Inc., a,diversified specialty ... marketing rights to the TIMOPTIC(R) product line from ... non-selective beta-adrenergic receptor,blocking agent indicated for the treatment ... or open-angle glaucoma. As many as 2.25,million Americans ...
... Head Company,s Network of International Subsidiaries and DistributorsWESTFORD, Mass., ... CYNO ), a leading developer and manufacturer of ... announced the appointment of William T. Kelley as Senior ... responsible for the company,s direct subsidiaries in four European ...
... also urges higher cigarette taxes, more oversight of advertising ... All tobacco products in the United States should be ... released Wednesday by a panel of 26 of the ... "Bold thinking is required to reverse the catastrophic projections ...
... Maine, Feb. 25 Millions of Americans live without ... services provided by non-profit dental clinics become increasingly important. ... of Maine Dental Health for AllTM program is helping ... with an estimated 134,000 additional patient visits since its ...
Cached Medicine News:Health News:M. D. Anderson Cancer Center Acquires Leksell Gamma Knife Perfexion for Targeted Brain Lesion Treatments 2Health News:M. D. Anderson Cancer Center Acquires Leksell Gamma Knife Perfexion for Targeted Brain Lesion Treatments 3Health News:Genstruct and Gene Logic Collaborate on Systems Toxicology 2Health News:Genstruct and Gene Logic Collaborate on Systems Toxicology 3Health News:Genstruct and Gene Logic Collaborate on Systems Toxicology 4Health News:Aton Pharma Acquires U.S. TIMOPTIC(R) 2Health News:Aton Pharma Acquires U.S. TIMOPTIC(R) 3Health News:Cynosure Appoints William T. Kelley as Senior Vice President of International Sales 2Health News:Cynosure Appoints William T. Kelley as Senior Vice President of International Sales 3Health News:Experts Call for FDA Regulation of Tobacco Products 2Health News:Tom's of Maine Dental Health for All(TM) Program Works With Customers and Retailers to Provide Access to Oral Health Care 2Health News:Tom's of Maine Dental Health for All(TM) Program Works With Customers and Retailers to Provide Access to Oral Health Care 3
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: